[225Ac]Ac-A9-3408 / Alpha-9 Oncology - LARVOL DELTA

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Alpha-9 Oncology USA Inc. | N=50 ➔ 5 | Trial completion date: Jan 2028 ➔ Jul 2026 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2028 ➔ Jul 2026; Due to a strategic decision to re-prioritize the sponsor's existing portfolio.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Eye Cancer • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • Uveal Melanoma

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Alpha-9 Oncology USA Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2025 ➔ Nov 2025

Enrollment open • Trial initiation date • Eye Cancer • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • Uveal Melanoma

Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3408 for the Treatment of Melanoma (PRNewswire) - "The Phase 1 study is a multi-center, open-label trial designed to evaluate the safety, dosimetry, and dose escalation of A9-3408 in patients with MC1R-positive melanoma, who have progressed on standard-of-care therapies."

Trial status • Mucosal Melanoma • Uveal Melanoma

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma (clinicaltrials.gov) - P1 | N=50 | Not yet recruiting | Sponsor: Alpha-9 Oncology USA Inc.

New P1 trial • Eye Cancer • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • Uveal Melanoma